Advanced prostate cancer patients frequently deal with intractable prostatic bleeding which is a difficult problem to manage. Intraurethral high-dose rate (HDR) brachytherapy may palliate this condition. Advanced prostate cancer patients with intractable prostatic bleeding were offered brachytherapy with Iridium-192 using a Micro-selectron HDR machine. During a 5-year period, analysis was performed in 23 patients with a median age and Gleason score of 78 years and 9, respectively. Following brachytherapy, haematuria resolved in 19 of the 23 patients and was recurrence free at 6 months. Intraurethral HDR brachytherapy is a potentially effective modality for treating haematuria in patients with advanced prostate cancer.
Introduction
Prostate cancer is the most common male malignancy in North America and western Europe. Presently, over 230 000 new cases of prostate cancer are diagnosed each year in the United States with a median age at diagnosis of 72. 1 Though the advent of prostate-specific antigen (PSA) screening and prostate cancer awareness has resulted in a greater rate of detection of organ-confined symptom-free disease, presently 22% of newly diagnosed cases are either locally advanced or metastatic. 2 Patients with advanced prostate cancer frequently develop prostatic bleeding which can significantly increase morbidity. Although most prostate cancers arise in the peripheral zone, bleeding can result when cancer encroaches upon the transition zone. This can be a difficult problem to manage, and there is little goodquality evidence to guide the treatment. Various treatment options including hormonal manipulation, palliative transurethral resection of prostate (TURP) and embolization have been used with varying degrees of success.
Over the last decade, low-and high-dose brachytherapy have been effective in the treating both organconfined and advanced prostate cancer as well as other malignant diseases. Based on encouraging results seen following the treatment of malignant diseases of the oesophagus, bronchus and urethra in the 1990s with intraluminal high-dose rate (HDR) brachytherapy, our institution devised a treatment protocol to treat intractable prostatic bleeding in patients with locally advanced prostate cancer. [3] [4] [5] This treatment was sanctioned by the Medical Physics and Clinical Engineering Department as well as the Oncology Department at our institution and offered to patients as a final attempt to palliate their intractable condition.
Patients and methods
This treatment was first used at the end of 1999. In the first year minor modifications were made to the treatment protocol to reduce radiation exposure and minimize side effects. A retrospective descriptive study was performed to identify all patients over a 5-year period between January 2001 and December 2006 who had undergone intraurethral HDR brachytherapy for locally advanced prostate cancer with intractable prostatic bleeding.
Prostatic bleeding in patients with known locally advanced prostate cancer was initially confirmed following investigations for haematuria including cystoscopy. Patients who were unfit for a TURP, declined surgery or continued to have intractable prostatic bleeding following surgery or hormonal manipulation were offered intraurethral high-dose brachytherapy as a final attempt at treating their condition.
Patients who accepted this treatment option following a detailed discussion about the procedure underwent a limited CT scan of their pelvis and plain abdominal X-ray ( Figure 1 ). This imaging is required to measure the length of the prostate in order to obtain the optimal time and positions for the radioactive source using treatment planning software.
Over the 5-year period, the palliative treatment regime continued to evolve with treatment doses decreasing from 24 Gy in four fractions to 18 Gy in two fractions, and finally to 9 or 10 Gy in a single fraction. The lower dosage in a single fraction provides a similar bioradiological outcome using an a/b of 3 (normal tissue late effects/ prostate tumour) as with higher dosages.
Patients were admitted on the morning of treatment and catheterized urethrally with a double lumen Foley catheter (size 16 Ch). Patients were then positioned in a shielded room with the Micro-selectron HDR machine (Nucletron, Veenendaal, The Netherlands) that houses the radioactive source ( Figure 2 ). An Iridium-192 radioactive wire was robotically inserted through the Foley catheter to the optimally measured position within the prostatic urethra. The wire lengths for radiation exposure to surrounding prostatic tissue varied between 30 and 80 mm and there were equal dwell times per position with exposure extending up to 10 mm into the prostatic tissue from the wire axis. A single treatment exposure usually lasted 10-15 min. Patients who were given more than a single fraction were required to keep the urethral catheter for the duration of their treatment regime while those who were given a single fraction had their catheters removed the following day in the radiotherapy department. Patients failing their trail without catheter had a repeat trial a week later. No specific precautions were required following the treatment. All patients were followed up in the outpatients' clinic at 3 and 6 months to assess the outcome of treatment.
Results
A total of 28 patients were treated with high-dose intraurethral HDR brachytherapy between January 2001 and December 2006. Patient data was obtained from 23 of these patients. The remaining five patients were lost to follow-up or had moved from the area and therefore no outcome information was available. Of the 23 patients, 18 were treated with a total dose of 24 Gy while 5 patients who were treated more recently were given less than 24 Gy (between 9 and 18 Gy) following alterations to treatment protocol.
The median age and Gleason score for the 23 patients were 78 years (63-90) and 9 (7-10), respectively, as shown in distribution graphs in Figures 3 and 4 . Following brachytherapy, macroscopic haematuria resolved within 3 months in 15 of the 18 patients who were given 24 Gy, and 4 of the 5 patients who were given less than 24 Gy. These patients continued to have no recurrent haematuria at the 6-month follow-up. All the four None of the 23 patients suffered significant side -effects, such as recto-vesical or recto-urethral fistulae, urethral strictures or bladder neck stenosis. The majority of patients however suffered some dysuria and urinary frequency up to 3 months following their treatment. At the time of analysis, 9 of the 18 patients who were treated with 24 Gy and 4 of the 5 patients who were treated with less than 24 Gy were still alive.
Discussion
As far as we know this is the first report of intraurethral HDR brachytherapy being used for intractable prostatic bleeding in patients with locally advanced prostate cancer. Intraluminal HDR brachytherapy has been used extensively as a palliative modality in treating advanced oesophageal, biliary and bronchial cancers. In inoperable oesophageal cancers, palliative brachytherapy results in 50-80% improvement in dysphagia. Sharma et al. 6 who evaluated 58 patients (38 treated with palliative brachytherapy alone and 20 treated with a combination of external beam radiotherapy and brachytherapy) found that the median dysphagia-free survival was 10 months while the complication rate was 30%. Another study of 232 patients with oesophageal cancer found similar improvements in dysphagia but with a lower complication rate of 10% with strictures and fistulae. 7 HDR brachytherapy has also been found to be effective in malignant obstructive jaundice from biliary cancers. In a recent study of 34 patients with biliary stents for malignant obstructive jaundice, mean stent patency was longer in patients following HDR brachytherapy than in those left untreated (12.6 months versus 8.3 months, respectively; Po0.05).
8 Airway obstruction from bronchial carcinoma can be effectively palliated with intraluminal brachytherapy. Giving fractionated doses of 500-700 cGy through bronchoscopes improves symptoms of dyspnoea, haemoptysis and postobstructive pneumonia with response rates of 66-95%. [9] [10] [11] [12] Though there has been anecdotal evidence suggesting that hormone manipulation may reduce prostatic bleeding in cancer, there is no published data to support this. Foley et al.
13 studied a group of 57 patients with haematuria from benign prostatic enlargement and discovered that patients who had received a 5a-reductase inhibitor (5ARIs) for 1 year were less likely to have recurrence of their haematuria than their counterparts who were given a placebo (14% versus 65% recurrence, respectively; P ¼ 0.05). In another study, Dutasteride was shown to reduce the microvascular density in prostate cancer as well as cause glandular atrophy in prostate cancer patients.
14 Though surgical and medical castration has been shown to reduce microvascular density as well as 5ARIs in animal studies, patients may suffer significant long-term side effects from these options. 15 Antifibrinolytics such as tranexamic acid promote thrombosis by inhibiting plasminogen activator. Patients who were given tranexamic acid prior to their TURP had 50% less blood loss than patients on placebo in one study. 16 Though this pharmacological agent may have a role in prostate cancer bleeding, there are concerns about its prothrombogenic potential in patients with advanced cancer who often have symptomatic cardiovascular and peripheral vascular disease.
Palliative radiotherapy is another modality for treating prostatic bleeding. Gibbons et al. 17 in their study confirmed that prostate cancer patients who had been treated with curative external beam radiotherapy (EBRT) were less likely to suffer haematuria, 2 years following treatment, than the untreated patients. However, patients who have had previous EBRT are unable to have any further radiotherapy due to the high risk of significant localized tissue damage.
Embolization may be a more effective method of managing prostatic bleeding, with a low side-effect profile particularly if super-selective embolization of the prostatic branches is attempted. This form of treatment has been shown to control haematuria in up to 90% of patients. 18 Other minimally invasive procedures to reduce prostatic bleeding include intravesical treatment using 1% alum to reduce vascular permeability, as well as high-intensity focused ultrasound and cryotherapy that involve tissue destruction.
The surgical option in the form of TURP is probably the most commonly employed method for prostate cancer patients with prostatic bleeding. However, Crain et al. 19 found in their study that recatheterization rates for bleeding following TURP was 9 times greater in patients who had prostate cancer than those with benign prostatic enlargement. Furthermore, many of these Brachytherapy for prostate cancer bleeding R Thurairaja et al patients considered for a palliative TURP may be frail and have a significantly limited fitness particularly if they have locally advanced or metastatic prostate cancer with other comorbidities.
Holmium laser enucleation of the prostate (HoLEP) and more recently high-powered potassium-titanylphosphate (KTP) vaporization of the prostate are two laser-based therapies that have recently become acceptable surgical alternatives to TURP. 20, 21 Since the laser's wavelength is well absorbed by water, it is a particularly effective tool for ablation and cutting of soft tissue. 22 Though there is no published data focusing on the effect of laser-based therapies on advanced prostate cancer bleeding, Elzayat et al. 23 confirmed in their study that HoLEP successfully treated 13 of 14 fully anticoagulated patients without secondary haematuria while Volkan et al. 24 reported that effective haemostasis was achieved in 21 cases of uncontrolled prostatic bleeding with 40 watt KTP laser vaporization. These findings may suggest a potential treatment benefit in patients with advanced prostate cancer bleeding.
Intraurethral brachytherapy involves the emission of high doses of radiation to a focal length of the prostate. Within approximately 5-10 mm the dosage decreases exponentially reducing the risk of localized tissue damage significantly. This study shows it is effective in controlling haematuria in most patients without significant side effects. This treatment can be used in patients who have had previous EBRT and those felt to be unfit for TURP. Following a cost assessment completed by the Management Accounts Department, it was calculated that the average cost for a patient to have intraurethral brachytherapy for prostatic bleeding is d1391 as compared to d2915 for a patient to have a TURP (excluding additional investigations for any comorbidities). In addition, when some of the other HDR brachytherapy centres in the United Kingdom were contacted, none of these units admitted to having any experience with intraurethral brachytherapy for advanced prostate cancer bleeding but instead were performing palliative EBRT.
In conclusion, intractable prostatic bleeding in patients with prostate cancer is a common and distressing problem that is costly in terms of investigations and treatment. Intraurethral HDR brachytherapy is an effective and relatively inexpensive modality for treating intractable prostatic bleeding and may be an attractive option for selected patients. Studies comparing this modality with other forms of treating intractable prostatic bleeding in prostate cancer are therefore essential.
